Toxin News and Research

RSS

US FDA approves raxibacumab for treating inhalational anthrax

The US Food and Drug Administration have approved the monoclonal antibody raxibacumab for treatment of inhalational anthrax, caused by breathing in spores of Bacillus anthracis.

19 Dec 2012

Study suggests that existing HIV drug could be a potential therapy for Staph infections

A new study by NYU School of Medicine researchers suggests that an existing HIV drug called maraviroc could be a potential therapy for Staphylococcus aureus, a notorious and deadly pathogen linked to hundreds of thousands of hospitalizations each year.

15 Dec 2012

FDA approves GSK’s raxibacumab to treat inhalational anthrax

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved raxibacumab for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

14 Dec 2012

GSK receives FDA approval for raxibacumab to treat inhalational anthrax

The U.S. Food and Drug Administration today approved raxibacumab injection to treat inhalational anthrax, a form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis. Raxibacumab also is approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate.

14 Dec 2012

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant cells responsible for acute lymphocytic leukemia (ALL) in either weekly or monthly dosing, researchers report at the 54th ASH Annual Meeting and Exposition.

12 Dec 2012

BlueGenics aims to discover new drugs from deep sea to combat osteoporosis

Searching for substances from the deep sea to combat osteoporosis and other human common diseases is one of the objectives of the new European research project "BlueGenics" which has received funding of EUR 6 million from the European Commission.

10 Dec 2012

Child Neurology Society honors LSUHSC professor with 2012 Hower Award

The Child Neurology Society presented Ann Henderson Tilton, MD, Clinical Professor of Neurology at LSU Health Sciences Center New Orleans, with the 2012 Hower Award at the 41st Annual CNS Meeting in November.

29 Nov 2012

Abacus Diagnostica’s GenomEra C. difficile assay receives CE mark

Abacus Diagnostica Ltd announced that it has received the CE mark for the GenomEra C. difficile assay for the detection of toxin-producing Clostridium difficile directly from stool samples. C. difficile is the leading cause of infectious nosocomial diarrhea in Europe and North America.

19 Nov 2012

Myasthenia gravis therapies: an interview with Professor Daniel Drachman

Myasthenia gravis (MG) is an autoimmune disease that produces weakness and fatiguability of muscles. It affects between 1 and 7 people per 10,000, according to the best statistics.

15 Nov 2012

Preschool children particularly vulnerable to food-borne toxins

In a sobering study published in the journal Environmental Health, researchers at UC Davis and UCLA measured food-borne toxin exposure in children and adults by pinpointing foods with high levels of toxic compounds and determining how much of these foods were consumed.

14 Nov 2012

Washington University, SRI investigators launch Global Metabolomic Initiative

Investigators at Washington University and The Scripps Research Institute have announced the launch of a "Global Metabolomic Initiative" to facilitate meta-analyses on studies of the metabolism of bacteria, yeast, plants, animals and people.

7 Nov 2012

New discovery could help revolutionize antibiotic treatment of bacteria

Three Simon Fraser University scientists are among six researchers who've made a discovery that could help revolutionize antibiotic treatment of deadly bacteria.

20 Oct 2012

Botulinum treatment benefits in BPH maybe down to placebo effect

Treatment with botulinum toxin has proved no more effective than placebo at reducing symptoms in men with lower urinary tract symptoms due to benign prostate hyperplasia, show study findings.

17 Oct 2012

Multi-system exposure related illness (MERI)

The Global Health Network has released a new paper titled “Common Toxins in our Homes, Schools and Workplaces.” According to an Environmental Protection Agency (EPA) spokesman, indoor air pollution causes 50% of illnesses globally. This statistic should catch the attention of every physician, every lawmaker and every layperson reading this paper. That’s more than all the cancers and all the heart disease combined. It is time we started to pay more attention to the indoor air we breathe. It is staggering to comprehend the enormous impact on our global society as literally millions of individuals and families are harmed by contaminants inside our homes, schools and workplaces.

16 Oct 2012

Highlights of Mount Sinai research at Neuroscience 2012

Researchers from Mount Sinai School of Medicine are presenting important discoveries on the involvement of the immune system and dopamine cells in the onset of depression at Neuroscience 2012, the Society for Neuroscience's 42nd annual meeting on October 13 -17 in New Orleans, and are available for interviews.

15 Oct 2012

Researchers discover how indoor mould makes people sick

For more than a decade, it has been known that the fungus Trichoderma longibrachiatum is the most common finding wherever people are suffering from health hazards related to damp building damage. However, it has not been known how this mould - which is typical of most buildings with indoor air problems - harms people's health. Published in September, a study by a team of researchers at the Department of Food and Environmental Sciences of the University of Helsinki explains how microbial metabolites in the living environment cause health problems

12 Oct 2012

Anesthetic-loaded liposomes can delay onset of neuropathic pain

Using tiny spheres filled with an anesthetic derived from a shellfish toxin, researchers at Boston Children's Hospital and the Massachusetts Institute of Technology have developed a way to delay the rise of neuropathic pain, a chronic form of pain that arises from flawed signals transmitted by damaged nerves.

10 Oct 2012

Scientists discover how protein deficiency may be linked to frontotemporal dementia

Using animal models, scientists at the Gladstone Institutes have discovered how a protein deficiency may be linked to frontotemporal dementia (FTD)-a form of early-onset dementia that is similar to Alzheimer's disease. These results lay the foundation for therapies that one day may benefit those who suffer from this and related diseases that wreak havoc on the brain.

9 Oct 2012

Progress toward preventing initial and recurrent episodes of C. diff infection

Surgeons are making progress toward preventing initial and recurrent episodes of clostridium difficile colitis (C. difficile or C. diff), a vicious bacterial infection that is estimated to affect about 336,000 people each year, typically patients on antibiotics.

6 Oct 2012

Botox injections effectively treat urinary urgency incontinence in women

Botox- (onabotulinum toxin-A) injections to the bladder are as effective as medication for treating urinary urgency incontinence in women, but the injection is twice as likely to completely resolve symptoms. These findings were published in the latest issue of The New England Journal of Medicine by a National Institutes of Health clinical trials network including Loyola University Chicago Stritch School of Medicine (SSOM).

5 Oct 2012